Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Oncotelic Therapeutics, Inc. | 500,000 | reported | 20 Jun 2018 | tx 8+2,012,500 |
| GENELABS TECHNOLOGIES INC /CA | 33,000 | reported | 27 Jan 2006 | tx 7+82,056−5,000 |
| NEUROBIOLOGICAL TECHNOLOGIES INC /CA/ | 25,000 | reported | 22 Oct 2008 | tx 1+25,000 |
| NOVACEA INC | 0 | reported | 30 Oct 2014 | tx 2+25,000−2,083 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 20 Jun 2018 | GRANT_AWARD | Oncotelic Therapeutics, Inc. | 250,000 | 0.00 USD | deriv |
| 20 Jun 2018 | GRANT_AWARD | Oncotelic Therapeutics, Inc. | 500,000 | 0.00 USD | deriv |
| 12 Apr 2018 | PURCHASE | Oncotelic Therapeutics, Inc. | 250,000 | — | first after silence |
| 12 Apr 2018 | PURCHASE | Oncotelic Therapeutics, Inc. | 125,000 | — | deriv |
| 12 Apr 2018 | PURCHASE | Oncotelic Therapeutics, Inc. | 125,000 | — | deriv |
| 12 Jan 2017 | GRANT_AWARD | Oncotelic Therapeutics, Inc. | 350,000 | 0.38 USD | deriv |
| 21 Mar 2016 | GRANT_AWARD | Oncotelic Therapeutics, Inc. | 262,500 | 0.00 USD | deriv |
| 20 Jul 2015 | GRANT_AWARD | Oncotelic Therapeutics, Inc. | 150,000 | 0.00 USD | deriv |
| 30 Oct 2014 | OTHER | NOVACEA INC | 2,083 | — | deriv |
| 16 Dec 2013 | GRANT_AWARD | NOVACEA INC | 25,000 | 0.00 USD | deriv |
| 22 Oct 2008 | PURCHASE | NEUROBIOLOGICAL TECHNOLOGIES INC /CA/ | 25,000 | 0.75 USD | |
| 27 Jan 2006 | GRANT_AWARD | GENELABS TECHNOLOGIES INC /CA | 33,000 | 1.91 USD | deriv |
| 30 Jun 2004 | OTHER | GENELABS TECHNOLOGIES INC /CA | 6,131 | 1.27 USD | |
| 23 Jan 2004 | GRANT_AWARD | GENELABS TECHNOLOGIES INC /CA | 30,000 | — | deriv |
| 31 Dec 2003 | OTHER | GENELABS TECHNOLOGIES INC /CA | 7,925 | 1.27 USD | |
| 31 Dec 2003 | GIFT | GENELABS TECHNOLOGIES INC /CA | 5,000 | — | |
| 31 Dec 2003 | GIFT | GENELABS TECHNOLOGIES INC /CA | 2,500 | — | |
| 31 Dec 2003 | GIFT | GENELABS TECHNOLOGIES INC /CA | 2,500 | — |
1 purchase reported after at least 12 months of silence — most recent on 12 Apr 2018.